Abstract
Introduction
independent literature evidence to help explain why such molecules might selectively inhibit 66 the cell lines with the particular mutation. Table 2 : Cells with BRAF mutations in the NCI60 cell lines. The particular amino acid mutation is shown (Ikediobi et al., 2006) .
The second approach, to look for novel molecules that are selective for cell lines with a 68 particular mutation using statistical modeling, presupposes that a valid method exists for 69 ranking such selectivity. This current paper explores whether a statistic computed from the 70 publicly available NCI60 screening data may be used to identify such selectivity. In future
71
work we plan to use statistical modeling to build models of selectivity of cell lines with a 72 particular mutation. The focus of this paper is to try to first show that such a statistic may 73 be meaningful.
tioned, there are approved drugs for V600E mutated BRAF making it possible to see if 89 known inhibitors were ranked highly. There are no widely acknowledged inhibitors of mu-90 tated KRAS to serve as a test of the ranking but because of the interest in KRAS as a target 91 we thought it would be interesting to see which molecules would be highly ranked.
92
Expected Results
93
To recap, our hypothesis was that there might be molecules in the NCI60 data set that had 94 higher average pGI50 values for those cell lines which contained an oncogene mutation of 95 interest than those cell lines that lacked that mutation. Our expectation was that those 96 molecules that were tested as having a higher average pGI50 with respect to the muta- 
123
After these filters 14,487 molecules remained, each of which had both been tested on 50 or 124 more cell lines and had a range of pGI50 values that were ≥ 1.2 log 10 units.
125
The pGI50 values used to compute the means were standardized as "z-scores" using
126
Equation (2) with the sample mean (μ) and sample standard deviation (σ) (Kreyszig, 1999) 127 calculated with respect to each cell line to try and account for different responses across 128 different cell lines.
The two sets of mutations that we looked at were the V600E mutation of BRAF and any
130
of the KRAS mutations at codons 12, 13, and 61 that had been sequenced in the Ikediobi 131 study (Ikediobi et al., 2006) . The KRAS mutations are shown in The September 2012 GI50 data was downloaded from the NCI DTP website (NCI-DTP, 166 2012). We used these GI50 values for our calculations. 
176
The calculations were done by means of short programs written in JavaScript using the
177
Node.js server-side JavaScript implementation (Dahl, 2014) . We chose JavaScript as the pro-
178
gramming language because we anticipated building a web application to visualize results
179
and expected that using JavaScript would simplify development (web browsers typically use 
185
There were small differences between the names of cell lines in the downloaded data sets.
186
For example in the COSMIC data the HT29 cell line was listed as "HT-29" whereas in the 187 NCI DTP data set it was referred to as "HT29." Therefore it was necessary to include 188 transformations in the code in order to standardize the cell line names.
from the PubChem 2D coordinates (OBoyle et al., 2011) .
191
The R statistical package was used to generate 2D plots and to estimate some p values 192 and confidence intervals (R Core Team, 2014).
193
As mentioned the results in this paper were generated using a Makefile. The molecular graphics image in Figure 5 was prepared using the UCSF Chimera pack- that the guanosine part of the molecule appears to be buried in a cavity but is partly exposed
268
Since HRAS and KRAS are very similar proteins (Schubbert et al., 2007) it seems quite 270 possible that GTP binds to KRAS in a similar manner.
Figure 5: A view of the crystal structure (PDB ID-1AGP) of the G12D HRAS mutant is shown with a GTP analog, guanosine 5'-(beta,gamma-imido)triphosphate, bound. This GTP analog appears to be bound in such as way in which its guanosine part may be able to interact with other molecules at the surface of the protein. Colors represent the atomic elements, carbon (grey), hydrogen (white), nitrogen (blue), oxygen (red), and phosphorus (orange).
271
The conjecture that cytosine derivatives interact with KRAS bound to either GTP or GDP 272 is a highly speculative conjecture and most likely wrong given the lack of direct evidence.
273
However the question of why cytosine analogs appear to preferentially inhibit the growth of 274 cell lines with KRAS mutations does seem an interesting one given the importance of KRAS 275 as a potential drug target.
276
The main hypothesis of this study was that there were molecules that had been screened 277 in the NCI60 cell line panel that selectively inhibited the growth of cell lines with a particular 278 mutation more than those that lacked that mutation. We looked at two oncogenes, mutated
279
BRAF and mutated KRAS and used a simple method to rank screened molecules in order 280 of how much those molecules inhibited the growth of cell lines with a particular mutation.
281
In the case of BRAF highly ranked molecules included selumetinib, vemurafenib and 282 hypothemycin. All three of these molecules inhibited proteins in the RAS → RAF → MEK
283
→ ERK pathway which indicates that the ranking was sensible. Vemurafenib was designed 284 to inhibit BRAF with the V600E mutation and has been approved by the US FDA to treat 285 melanoma with this specific mutation. We expected that the other approved BRAF V600E
286
inhibitor dabrafenib would also rank highly. However the screening results for this molecule
287
were not in the 2012 NCI60 data set.
288
In the case of KRAS highly ranked molecules included a number of drugs that were by chance but less likely that several different cytidines would be highly ranked by chance.
296
Therefore it seems worthwhile to look into why such molecules would selectively inhibit the 297 growth of cell lines with KRAS mutations.
298
The NCI60 screen is a phenotypic small-molecule screen, a screen in which some amount 299 of a small-molecule is added to a cell or organism and observed to see if there is a change 300 in phenotype (Eggert, 2013) . Eggert mentions some potential advantages of this approach.
301
One potential advantage cited is that phenotypic screens can potentially "target any protein
302
(or other entity, such as lipid or nucleic acid) in its biological context" (Eggert, 2013 discovery as long as these limitations are recognized (Weinstein, 2012; Weinberg, 2014b) .
315
Related Work
316
The work described in this paper has similarities to previous work by Ikediobi (Ikediobi, 317 2008) and Meltzer et al. (Abaan et al., 2013) . These two studies are similar because they 318 are also based on the NCI60 data set and look at the cancer-related gene mutations within 319 the cell lines. In particular both studies ranked screened molecules in descending order of 320 the difference between the mean GI50s of mutated and wild-type genes in the same way that 321 we have described. A difference is that these studies did not normalize the GI50s as we have 322 done, something that we suppose will not make a big difference to the results. facts about those molecules.
363
In the BRAF ranking the highest ranked molecules included vemurafenib and selumetinib.
364
Vemurafenib is a drug designed and approved to treat melanoma with the BRAF V600E 365 mutation. Selumetinib is a MEK 1/2 inhibitor and MEK 1/2 in a protein which shares a 366 signaling pathway with BRAF. Therefore these rankings seem to make sense with respect to 367 BRAF.
368
With the KRAS rankings the highest ranked molecules included cytarabine, gemcitabine,
369
and other cytidine analogs. Cytarabine is an approved chemotherapy drug that has been 370 observed to be of some benefit to AML patients with a KRAS mutation (Goodman et al., there is some evidence to suggest that the high ranking of these cytidine analogs concords
374
with results independent of the NCI60 data.
375
Literature research of the top hits gave clues as to the mechanism of action of the growth 
